{
    "clinical_study": {
        "@rank": "48700", 
        "arm_group": {
            "arm_group_label": "A6", 
            "arm_group_type": "Experimental", 
            "description": "A6 is administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days)."
        }, 
        "brief_summary": {
            "textblock": "This study will assess the efficacy, safety and pharmacodynamic markers of the study drug,\n      A6, in patients with CLL and small lymphocytic lymphoma (SLL)."
        }, 
        "brief_title": "Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Lymphocytic Leukemia", 
            "Small Lymphocytic Lymphoma", 
            "CLL", 
            "SLL"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "In patients diagnosed with CLL or SLL, study medication will be injected subcutaneously two\n      times a day in an outpatient setting for up to 6 cycles (28 days = 1 cycle) prior to the\n      primary endpoint assessment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of CLL or SLL based on IWCLL Criteria\n\n          -  Measurable or evaluable disease based on IWCLL criteria\n\n          -  Previously untreated patients who have been counseled on approved alternative\n             therapeutic options.   Not a candidate for fludarabine/cyclophosphamide/rituximab\n             (FCR) or has preference to not receive chemotherapy.\n\n          -  Eastern Cooperative Oncology Group (ECOG) status of 0-2.\n\n          -  Adequate bone marrow, renal, liver, cardiac and pulmonary function.\n\n          -  Life expectancy of greater than or equal to 6 months.\n\n        Exclusion Criteria:\n\n          -  Receipt of other cancer therapy, immunomodulatory drug therapy or immunosuppressive\n             therapy   within 4 weeks prior to 1st dose.\n\n          -  Receipt of corticosteroids > 20 mg/day within 4 weeks prior to1st dose\n\n          -  Major surgery or radiation within 4 weeks prior to 1st dose\n\n          -  Presence of uncontrolled infection requiring systemic therapy\n\n          -  Active second malignancy other than non-melanoma skin cancer\n\n          -  Uncontrolled autoimmune anemia or thrombocytopenia\n\n          -  Receipt of any investigational agent within 4 weeks prior to 1st dose\n\n          -  Pregnant or lactating female\n\n          -  Any severe, acute or chronic medical or psychiatric condition, or lab abnormality\n             that may increase the risk associated with trial participation, study drug\n             administration or interfere with informed consent process or compliance with\n             requirements of the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046928", 
            "org_study_id": "A6-005"
        }, 
        "intervention": {
            "arm_group_label": "A6", 
            "description": "A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).", 
            "intervention_name": "A6", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Leukemia", 
            "Lymphoma"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "La Jolla", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92093"
                }, 
                "name": "Moores Cancer Center, UCSD"
            }, 
            "investigator": {
                "last_name": "Michael Choi, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients With Chronic Lymphocytic Leukemia", 
        "overall_contact": {
            "email": "k1aguilar@ucsd.edu", 
            "last_name": "Kimberly Aguilar", 
            "phone": "858-534-5201"
        }, 
        "overall_official": {
            "affiliation": "Moores Cancer Center, UCSD", 
            "last_name": "Michael Choi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "International Workshop on Chronic Lymphocytic Lymphoma (IWCLL) Guidelines  for response of clinical, hematological, and bone marrow features.", 
            "measure": "Overall response rate", 
            "safety_issue": "No", 
            "time_frame": "Assessed at Day 28 of Cycle 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046928"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Nature and frequency of adverse events", 
                "measure": "Safety of A6", 
                "safety_issue": "Yes", 
                "time_frame": "Throughout 6 Cycles (6 months)"
            }, 
            {
                "measure": "Determine IWCLL response rate in the Intent-To-Treat Population", 
                "safety_issue": "No", 
                "time_frame": "Throughout 6 Cycles (6 months)"
            }, 
            {
                "measure": "Determine the response in patients who received all 6 cycles of A6", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Determine progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Throughout 6 Cycles (6 months)"
            }
        ], 
        "source": "\u00c5ngstrom Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "\u00c5ngstrom Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}